Another new study finds no evidence of benefit from Hydroxychloroquine malaria drug promoted as treatment for coronavirus infection.

  • Researchers at Columbia University in New York, reported the results of the study Thursday in the New England Journal of Medicine.
  • Nearly 1,400 patients were involved in the study. Doctors at Columbia tracked how 565 patients who did not get the drug fared compared to 811 others who received hydroxychloroquine with or without the antibiotic azithromycin.
  • Hydroxychloroquine did not lower the risk of dying or needing a breathing tube.
  • In all, 180 patients required breathing tubes and 232 died, and the drug did not seem to affect the odds of either.